Ligand Pharmaceuticals, Inc. (LGND)Congress Asset Management Co added to its stake +155K shares

660K

Shares reported · +155K vs prior quarter

1.3%

Disclosed portfolio weight

$209M

Reported value

Holdings as of

Jun 30, 2026

Filed

Jul 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 16, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
2. May 29, 2026CongressDisclosed purchase of LGND — reported range $1,001 - $15,000
3. Jun 5, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“The 2026 Annual Meeting of the Stockholders of Ligand Pharmaceuticals Incorporated (the “Company”) was held on June 5, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment and restatement of the Company’s 2002 Stock Incentive Plan (the “2002 Plan”).”
4. Jun 22, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
5. Jun 25, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)

What came next

1. Jul 14, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“On July 14, 2026, the Company consummated the previously announced Merger with HoldCo in accordance with the terms of the Merger Agreement. Pursuant to the Merger Agreement, XOMA Royalty effected the Holding Company Reorganization (as defined below) prior to giving effect to the Merger.”
2. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results
3. Oct 2, 2026Insider · 1 personInsiders: 6 sales (~$1.5M)

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Ligand Pharmaceuticals, Inc.

For Ligand Pharmaceuticals, Inc., OQRO holds 6 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LGND page.

How this filing works

• SEC Form 13F

Other disclosures at Ligand Pharmaceuticals, Inc.

• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 7, 2026

Everything OQRO holds on this company is on its LGND page.